Nalidixic acid in urinary tract infections with particular reference to the emergence of resistance.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001431:Bacteriological Techniques; D001437:Bacteriuria / Q000188:drug therapy* / Q000382:microbiology; D002908:Chronic Disease; D003470:Culture Media; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D004352:Drug Resistance, Microbial; D004925:Escherichia / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D007710:Klebsiella Infections / Q000188:drug therapy; D008875:Middle Aged; D009268:Nalidixic Acid / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy* / Q000382:microbiology
D003470:Culture Media; D009268:Nalidixic Acid